FDA grants priority review of Amgen's panitumumab for colorectal cancer

By Lisa Kerner

Charlotte, N.C., June 12 - Amgen Inc. said the Food and Drug Administration has granted priority review to its Biologic License Application for panitumumab, an investigational fully human monoclonal antibody for the treatment of metastatic colorectal cancer patients who have failed prior chemotherapy.

Panitumumab received fast track designation from the FDA in July 2005. It is being evaluated in clinical trials as both a monotherapy and with other agents for the treatment colorectal, lung and head and neck cancers, according to a company news release.

Amgen is a biotechnology company located in Thousand Oaks, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.